Provided by Tiger Trade Technology Pte. Ltd.

Legend Biotech

19.32
-0.5700-2.87%
Post-market: 19.15-0.1654-0.86%19:41 EDT
Volume:2.22M
Turnover:43.06M
Market Cap:3.76B
PE:-38.58
High:19.78
Open:19.61
Low:19.19
Close:19.89
52wk High:37.50
52wk Low:16.24
Shares:194.49M
Float Shares:91.34M
Volume Ratio:1.13
T/O Rate:2.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5008
EPS(LYR):-1.6200
ROE:-8.08%
ROA:-1.92%
PB:3.06
PE(LYR):-11.93

Loading ...

Legend Biotech Corp - Ying Huang Steps Down as CEO and Board Member; to Remain as Advisor Through August

THOMSON REUTERS
·
Jul 27

Legend Biotech Corp - Alan Bash Appointed Interim CEO

THOMSON REUTERS
·
Jul 27

Legend Biotech Corp - Board Initiates Search for Permanent CEO Successor

THOMSON REUTERS
·
Jul 27

Legend Biotech Announces CEO Transition

THOMSON REUTERS
·
Jul 27

Legend Biotech Shares Fall After UBS Downgrade

MT Newswires Live
·
Jul 25

Legend Biotech Cut to Neutral from Buy by UBS

Dow Jones
·
Jul 24

UBS Downgrades Legend Biotech to Neutral From Buy, Adjusts Price Target to $28 From $49

MT Newswires Live
·
Jul 24

Legend Biotech downgraded to Neutral from Buy at UBS

TIPRANKS
·
Jul 24

Analysts Offer Insights on Healthcare Companies: Medicinova (MNOV), Legend Biotech (LEGN) and AngioDynamics (ANGO)

TIPRANKS
·
Jul 16

Genscript Highlights Strong CARVYKTI Sales via Legend Biotech, Urges Investor Caution

TIPRANKS
·
Jul 15

Legend Biotech: Carvykti® Generated About $657 Million in Net Trade Sales During Qtr Ended June 30, 2026

THOMSON REUTERS
·
Jul 15

Barclays Sticks to Its Buy Rating for Legend Biotech (LEGN)

TIPRANKS
·
Jul 14

Legend Biotech Price Target Announced at $35.00/share by JP Morgan

Dow Jones
·
Jul 13

Legend Biotech is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 08

RBC Capital Adjusts Legend Biotech Price Target to $63 From $64, Maintains Outperform Rating

MT Newswires Live
·
Jul 07

Legend Biotech Insider Move: Director Offloads Stake in High-Profile Transaction

TIPRANKS
·
Jul 03

Legend Biotech Director Casey Patrick John Disposes of 6,000 Common Shares for $88,800

Reuters
·
Jul 03

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.d., to Board of Directors

THOMSON REUTERS
·
Jun 23

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

GlobeNewswire
·
Jun 23

Legend Biotech Prices $226 Million ADS Offering to Bolster Cell Therapy Expansion

TIPRANKS
·
Jun 23